Skip to main content

From drones to smart pills, 2018 saw significant tech advances in medicine

Ascom / MCTIC

Robots, A.I. algorithms, and drone deliveries are increasingly found in just about every industry and profession. Why not the medical world, too? To that end, 2018 saw an impressive convergence of cutting-edge technology and groundbreaking medical research.

It is, of course, crucial that any new technology is properly investigated before it finds its way to patients, but — when the right steps are taken — these tools can be a game changer when it comes to health and wellness. Here are some of the biggest medical tech stories that caught our eye this year.

Recommended Videos

Medical drone deliveries

We’re still not at the point where most of us can get a book or DVD (if people still buy those!) delivered by drone, but drone-based medical deliveries nonetheless made big strides in 2018.

A pioneering medical trial by the University of Maryland demonstrated that drones could be used for safely transporting a potentially lifesaving transplant organ. They did this by putting a kidney in a cooler and flying it underneath a DJI M600 Pro drone to see if it suffered any damage. It didn’t — and the organ actually experienced fewer vibrations than it would when being transported in a fixed-wing plane.

Zipline

Meanwhile, Zipline unveiled a new, faster drone for delivering vital medical services such as blood supplies. For the past two years, Zipline has delivered blood for vital transfusions to remote clinics in Rwanda. The company’s new drone — which it claims is the fastest commercial delivery drone around — will make this mission more efficient. It’s got its eye on offering similar services in the U.S., too.

Wonders (and blunders) of gene editing

2018 was a significant year for advances in CRISPR gene editing. Operating in animal (predominantly mice) models, researchers demonstrated how severe obesity, autism, Duchenne muscular dystrophy, dementia, cocaine addiction, and other conditions can potentially be treated with careful use of gene therapy.

While these advances were generally met with favorable responses from the scientific community, a reported experiment coming out of China most certainly was not.

In the most infamous “medical advance” of 2018, researchers in China reportedly delivered the world’s first twins who had been genetically altered as embryos to remove a gene associated with potentially fatal diseases such as HIV, smallpox, and cholera.

The news received immediate backlash and intense criticism from around the world. Provided that the report is accurate (details have been far from forthcoming), this nonetheless represents a major landmark. Just not a landmark many hoped would be reached without far more research.

Bioengineered tissues and organs

There’s a massive shortage of available transplant organs. One potential solution would be to be able to grow new ones in the lab. While we’re not yet at the point at which this is entirely possible, 2018 moved the research in the right direction. The field of 3D bioprinting continued to make strides through the demonstration of 3D-printed human cardiac tissue.

3D-printed prototype for bionic eye

One of the other significant advances from our perspective was the creation of bioengineered lungs at the University of Texas Medical Branch at Galveston. These were then successfully transplanted into pigs, allowing them to breathe normally with no medical complications.

Transferring that research to clinical trials for humans is likely to take another five to eight years of preclinical testing. It’s an important advance, however.

Smart pills

Our phones have been smart for a decade now, our watches for a bit less than that, and our homes are getting smarter all the time. Why not smart pills as well?

That’s what researchers from RMIT University in Melbourne, Australia, demonstrated this year with the creation of a functioning electronic capsule which, once swallowed, measures gas biomarkers as it travels through the gut. As it does this, it gathers information relating to food, gut environment, and more — before transmitting it out of the body to a smartphone or other device. It could be useful for diagnosing diseases from irritable bowel syndrome and inflammatory bowel disease to potentially fatal ones such as colon cancer.

While it’s not quite ready for prime time, researchers have completed a successful phase 1 trial on 26 healthy individuals, proving the capsules’ safety and efficacy. Another not dissimilar project — also from researchers in Australia — explores how the smart pill experience could be “gamified” for the benefit of users.

Medical robots

Medical robots are getting better all the time. This year, neurosurgeons and otolaryngologists at the University of Pennsylvania’s Perelman School of Medicine reported performing the world’s first robot-assisted spinal surgery. This complex procedure involved the use of robot arms to remove a tumor from the neck of a 27-year-old patient.

Pediatric HAL®: The World's Most Advanced Pediatric Patient Simulator

For the procedure, neurosurgeons entered the patient’s body through the neck and cut the spine around the tumor. A team of three (human) surgeons then utilized the surgical robot to remove the tumor through the patient’s mouth. The spinal column was then reconstructed, using a hip bone and additional rods for stability.

“There are two components that make this work so exciting,” Dr. Neil Malhotra, one of the surgeons involved in the procedure, told Digital Trends. “One is that it permits us to switch from palliation for certain types of tumors to, in some cases for the first time, seeking cures. For the second point, this approach is less traumatic for the patient, which means a better recovery.”

Algorithm that predict mortality

No, no one in their right mind is suggesting replacing flesh-and-blood doctors with algorithms. However, machine learning tools definitely have their predictive place in modern medicine. With that in mind, the U.S. Food and Drug Administration this year granted its clearance for an algorithm that’s used in hospitals to help predict (and, hopefully, prevent) sudden patient deaths.

The Wave Clinical Platform works by monitoring patients’ vital signs and sending alerts warning about impending heart attacks or respiratory failure up to six hours before a patient suffers such an event. What makes the system so smart is that it not only monitors multiple biometrics for patients, but analyzes these in conjunction with one another. For example, a minor decrease in a patient’s respiratory rate wouldn’t usually be enough to trigger an emergency call. But if it’s accompanied by a spike in blood pressure, this could suggest something far more worrying.

A clinical trial among elderly patients at the University of Pittsburgh Medical Center showed that a group using the technology experienced fewer unexpected deaths than those who did not.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Juiced Bikes offers 20% off on all e-bikes amid signs of bankruptcy
Juiced Bikes Scrambler ebike

A “20% off sitewide” banner on top of a company’s website should normally be cause for glee among customers. Except if you’re a fan of that company’s products and its executives remain silent amid mounting signs that said company might be on the brink of bankruptcy.That’s what’s happening with Juiced Bikes, the San Diego-based maker of e-bikes.According to numerous customer reports, Juiced Bikes has completely stopped responding to customer inquiries for some time, while its website is out of stock on all products. There are also numerous testimonies of layoffs at the company.Even more worrying signs are also piling up: The company’s assets, including its existing inventory of products, is appearing as listed for sale on an auction website used by companies that go out of business.In addition, a court case has been filed in New York against parent company Juiced Inc. and Juiced Bike founder Tora Harris, according to Trellis, a state trial court legal research platform.Founded in 2009 by Harris, a U.S. high-jump Olympian, Juiced Bikes was one of the early pioneers of the direct-to-consumer e-bike brands in the U.S. market.The company’s e-bikes developed a loyal fandom through the years. Last year, Digital Trends named the Juiced Bikes Scorpion X2 as the best moped-style e-bike for 2023, citing its versatility, rich feature set, and performance.The company has so far stayed silent amid all the reports. But should its bankruptcy be confirmed, it could legitimately be attributed to the post-pandemic whiplash experienced by the e-bike industry over the past few years. The Covid-19 pandemic had led to a huge spike in demand for e-bikes just as supply chains became heavily constrained. This led to a ramp-up of e-bike production to match the high demand. But when consumer demand dropped after the pandemic, e-bike makers were left with large stock surpluses.The good news is that the downturn phase might soon be over just as the industry is experiencing a wave of mergers and acquisitions, according to a report by Houlihan Lokey.This may mean that even if Juiced Bikes is indeed going under, the brand and its products might find a buyer and show up again on streets and trails.

Read more
Volkswagen plans 8 new affordable EVs by 2027, report says
volkswagen affordable evs 2027 id 2all

Back in the early 1970s, when soaring oil prices stifled consumer demand for gas-powered vehicles, Volkswagen took a bet on a battery system that would power its first-ever electric concept vehicle, the Elektro Bus.
Now that the German automaker is facing a huge slump in sales in Europe and China, it’s again turning to affordable electric vehicles to save the day.Volkswagen brand chief Thomas Schaefer told German media that the company plans to bring eight new affordable EVs to market by 2027."We have to produce our vehicles profitably and put them on the road at affordable prices," he is quoted as saying.
One of the models will be the ID.2all hatchback, the development of which is currently being expedited to 36 months from its previous 50-month schedule. Last year, VW unveiled the ID.2all concept, promising to give it a price tag of under 25,000 euros ($27,000) for its planned release in 2025.VW CEO Larry Blume has also hinted at a sub-$22,000 EV to be released after 2025.It’s unclear which models would reach U.S. shores. Last year, VW America said it planned to release an under-$35,000 EV in the U.S. by 2027.The price of batteries is one of the main hurdles to reduced EV’s production costs and lower sale prices. VW is developing its own unified battery cell in several European plants, as well as one plant in Ontario, Canada.But in order for would-be U.S. buyers to obtain the Inflation Reduction Act's $7,500 tax credit on the purchase of an EV, the vehicle and its components, including the battery, must be produced at least in part domestically.VW already has a plant in Chattanooga, Tennesse, and is planning a new plant in South Carolina. But it’s unclear whether its new unified battery cells would be built or assembled there.

Read more
Nissan launches charging network, gives Ariya access to Tesla SuperChargers
nissan charging ariya superchargers at station

Nissan just launched a charging network that gives owners of its EVs access to 90,000 charging stations on the Electrify America, Shell Recharge, ChargePoint and EVgo networks, all via the MyNissan app.It doesn’t stop there: Later this year, Nissan Ariya vehicles will be getting a North American Charging Standard (NACS) adapter, also known as the Tesla plug. And in 2025, Nissan will be offering electric vehicles (EVs) with a NACS port, giving access to Tesla’s SuperCharger network in the U.S. and Canada.Starting in November, Nissan EV drivers can use their MyNissan app to find charging stations, see charger availability in real time, and pay for charging with a payment method set up in the app.The Nissan Leaf, however, won’t have access to the functionality since the EV’s charging connector is not compatible. Leaf owners can still find charging stations through the NissanConnectEV and Services app.Meanwhile, the Nissan Ariya, and most EVs sold in the U.S., have a Combined Charging System Combo 1 (CCS1) port, which allows access to the Tesla SuperCharger network via an adapter.Nissan is joining the ever-growing list of automakers to adopt NACS. With adapters, EVs made by General Motors, Ford, Rivian, Honda and Volvo can already access the SuperCharger network. Kia, Hyundai, Toyota, BMW, Volkswagen, and Jaguar have also signed agreements to allow access in 2025.
Nissan has not revealed whether the adapter for the Ariya will be free or come at a cost. Some companies, such as Ford, Rivian and Kia, have provided adapters for free.
With its new Nissan Energy Charge Network and access to NACS, Nissan is pretty much covering all the bases for its EV drivers in need of charging up. ChargePoint has the largest EV charging network in the U.S., with over 38,500 stations and 70,000 charging ports at the end of July. Tesla's charging network is the second largest, though not all of its charging stations are part of the SuperCharger network.

Read more